Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 524
Article

Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

07:00AM 05/10/13

Video

Biotech's Next Big Thing: ASCO

By Adam Feuerstein

TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.

09:39AM 05/09/13

Article

Repros Patent Problems Began When Harry Met Joe

By Adam Feuerstein

A New York fertility doctor accuses Repros CEO of stealing the idea for a new oral testosterone therapy.

08:00AM 05/09/13

Article

Amarin Trouble Grows As Does Evidence Against Fish Oil's Benefits

By Adam Feuerstein

Fish oil supplements have no heart benefits for patients, which doesn't bode well for Amarin's efforts to market Vascepa.

12:15AM 05/09/13

Article

Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Used

By Adam Feuerstein

Osiris CEO claims Prochymal is most widely used stem cell drug in world yet has generated no sales -- ever.

01:19PM 05/07/13

Article

Happy Day for Arena Bulls, Bears as Belviq Launch Finally Arrives

By Adam Feuerstein

DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.

11:53AM 05/07/13

Article

Fire Aveo's CEO for Incompetence and Arrogance Rivaling ImClone's Sam Waksal

By Adam Feuerstein

Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.

12:26PM 05/06/13

Article

Leaders of TheStreet's Drug Approval Contest

By Adam Feuerstein

This group of contestants have nearly perfect records picking FDA and European drug approvals.

09:21AM 05/06/13

Article

Aveo, Delcath FDA Panel Live Blog

By Adam Feuerstein

Join TheStreet's Adam Feuerstein as he live blogs FDA advisory panels for Aveo Oncology and Delcath Systems

07:44AM 05/02/13

Article

An Outrageous, Shameless Act by Hemispherx's Board of Directors

By Adam Feuerstein

Hemispherx CEO earns a bonus for overseeing the sale of company stock.

12:03PM 05/01/13

Page 2 of 524

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,294.50 -12.67 -0.08%
NASDAQ 3,459.42 -3.88 -0.11%
S&P 500 1,650.51 -4.84 -0.29%
US 10 Yr 2.023% -0.003

Brokerage Partners

Advertising Partners

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.

Top Rated Stocks Top Rated Funds Top Rated ETFs